We have previously demonstrated that Eμ-Myc lymphoma-bearing mice on CX-5461 therapy exhibit significantly increased survival, but eventually relapse with tumors that are intrinsically resistant to subsequent CX-5461 challenge [6,26]. The gene discussed is MYC; the disease is lymphoma.